Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily 20 Year Treasury Bull 3X Shares vs Tango Therapeutics Inc. — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $27.93 (market cap $2.08B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily 20 Year Treasury Bull 3X Shares for 30 Days and Tango Therapeutics Inc. for 0 Days on average.
| TMF | TNGX | |
|---|---|---|
Market Cap | $2.08B | $3.75B |
Volume | 5,652,065 | 9,619,106 |
Sector | Fixed Income | Health |
52-Week High | $44.14 | $32.90 |
52-Week Low | $25.19 | $7.50 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $26.38, up 1.15% with elevated volume. Technical indicators are bearish overall, with moving averages and oscillators signaling caution. The stock lacks traditional fundamental metrics like P/E or revenue, as it is an ETF, and its value is tied to interest rate expectations. Recent news highlights strong trading volume, suggesting heightened investor attention amid bond market volatility.
The outlook for TMF hinges on interest rate trends, with potential upside if rates fall but significant downside risk if they rise. Investors face volatility from macroeconomic shifts and the ETF's leveraged structure, which amplifies gains and losses. Key risks include Federal Reserve policy changes and inflation dynamics, making it suitable only for those comfortable with high risk and short-term trading.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
